(lp0
S"How VIVUS Inc  Delivered A Better ROE Than Its Industry? Simply Wall St - Mar 8, 2017 Over the past 12 months, VIVUS Inc  generated an ROE of 273.4%, implying the company created 273.4 cents on every dollar of shareholders' invested capital.VIVUS, Inc.  Scheduled to Post Earnings on Wednesday - BNB Daily VIVUS, Inc.  to Release Earnings on Wednesday - BBNS"
p1
aS"Thursday's Market Insights: Apricus Biosciences Inc , VIVUS, Inc. (VVUS ... Smarter Analyst - Mar 9, 2017 Apricus Biosciences Inc  shares are rising by 3% in Thursday's trading on the news that Apricus has completed the sale to Ferring International of its topical cream Vitaros.VIVUS  Posts Strong Profit Growth; Apricus Biosciences  Soars on ... - Galaxy Stocks  After-Hours Movers 03/08:    Higher;   (WATT ... - StreetInsider.com"
p2
aS"Traders Secrets on VIVUS, Inc. , McDermott International, Inc.  StockNewsJournal - Mar 10, 2017 Investors who are keeping close eye on the stock of VIVUS, Inc.  established that the company was able to keep return on investment at -21.11 in the trailing twelve month while Reuters data showed that industry's average stands at 13.50&nbsp;..."
p3
aS"VIVUS  Beats on Q4 Earnings, Revenues Increase Y/Y Zacks.com - Mar 9, 2017 VIVUS Inc.  reported earnings of 54 cents per share in the fourth quarter of 2016 as against a loss of 12 cents in the year-ago period.VIVUS, Inc.  Efforts To Reshape VIVUS' Business Model - StockNewsUnionNorth Tide Capital, Llc Sells 1149400 Shares of VIVUS, Inc.  Stock - Chaffey Breeze"
p4
aS"VIVUS, Inc.  Shares Down 0% Following Insider Selling Chaffey Breeze - 22 hours ago VIVUS logo VIVUS, Inc. 's share price was down 0% during trading on Monday after an insider sold shares in the company.The North Tide Capital, Llc Sells 1149400 Shares of VIVUS, Inc.  Stock - Petro Global News 24Trading updates about Stock: VIVUS, Inc.  - Is stories"
p5
aS'Vivus Inks Deal For Stendra - Why Street Reaction Is Muted Seeking Alpha - Oct 4, 2016 Vivus  announced today that it has reached a deal withy Metuchen Pharmaceuticals for the rights to the erectile dysfunction drug Stendra in the United States, Canada, South America, and India.VIVUS and Metuchen Pharmaceuticals Announce License Agreement for Commercial ... - Marketwired VIVUS Licenses Stendra Rights to Metuchen Pharmaceuticals - Nasdaq'
p6
aS'Vivus: A Speculative Play Just Got A Little More Speculative Seeking Alpha - Jun 22, 2016 Vivus  investors got yet another round of bad news today when the company filed an 8K with the SEC announcing that Hetero USA has filed an ANDA with the FDA to make generic versions of all Stendra doses.'
p7
aS"Stock within Traders Observation: VIVUS, Inc.  Is stories - 1 hour ago VIVUS, Inc.'s  witnessed no change 0.00% in recent trading period with closing price of $ 1.11. The company's last traded volume of 0.82 million shares as compared to it's an average volume of 0.55 million shares."
p8
aS"Vivus: Qsymia Sales Trudge Along - Investors Need Growth, Not Flatness Seeking Alpha - Jun 6, 2016 Some Vivus  investors seem to be in that boat. They are even celebrating the fact that Vivus' Qsymia did not do as bad as another player in the space last week despite the fact that Qsymia sales are still much lower than they need to be ..."
p9
aS'Vivus - Qsymia Scripts Continue Slow Path Seeking Alpha - Jun 13, 2016 Vivus  investors are likely used to the Qsymia sales mantra. Flat sales with a bias to the downside. Vivus investors are also likely used to the mantra that cost cutting will be used to try to improve the bottom line. Some investors are ...'
p10
a.